Osivax
@OsivaxVaccines
Followers
164
Following
29
Statuses
163
Clinical stage biotech developing vaccines and immunotherapies based on its proprietary technology oligoDOM® leveraging the power of cellular immune responses.
Lyon, France
Joined May 2019
🚨𝐉𝐨𝐛 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐲🚨 Want to be part of Osivax development? Osivax is looking for a Project Management Office Manager (F/M) Ready to take up an exciting challenge with us, send your application➡️ #Lyon #Fulltime #permanentposition
#Joboffer
0
0
0
📰 Pleased to share a recent article discussing the universal influenza vaccines and our vaccine candidate OVX836 More about our pipeline: The full article: #Influenza #UniversalVaccine #GlobalHealth
0
0
1
🍂#FluSeason Is Here With the #influenza season underway in the Northern Hemisphere, surveillance data from the Réseau Sentinelles, @ECDC_Flu & @CDCFlu show rising flu activity in several regions Stay informed and explore weekly updates from the #PublicHealth surveillance systems
0
0
1
🎥Our CMO shares insights on OVX836, our universal flu vaccine candidate, and the tech driving it. Watch the interview with @VaccineNation: 🔗 #WVCEU #Influenza #UniversalVaccine #Vaccine #HealthcareInnovation #PublicHealth
0
0
0
🌍 Heading to San Francisco for #JPMWeek? From January 13, our CEO and our CBDO/COO will be in the city. 👉 Still time to meet—reach out at contact@osivax.com to schedule a discussion. #JPM25 #Biotech #Innovation
0
0
0
Year in Review🎉 As 2024 comes to a close, Osivax celebrates a year filled with exciting achievements Our heartfelt gratitude to our team, partners, and supporters for their trust and collaboration Wishing everyone a prosperous and healthy New Year! Stay tuned for more updates!
0
0
1
#DYK Dec 27 = International Day of Epidemic Preparedness This day underscores the critical importance of preventing, preparing for, and partnering in the fight against #epidemics Let’s raise awareness and strengthen our collective preparedness for future health challenges. @UN
0
0
0
📰Publication of OVX836 results in Older Adults These findings, published in @Vaccines_MDPI, mark an important step forward in our mission to develop innovative, broad-spectrum solutions for influenza prevention #Innovation #UniversalVaccine #PublicHealth
0
0
0
🎧Exploring the Future of Flu Vaccines: In the newest episode of @ESWInfluenza podcast, experts discuss the ongoing advancements in flu vaccine technology Proud to contribute to the progress in this field through our NP-based vaccine technology #innovation
1
0
0
🎓Pleased to share that one of our expert had the opportunity to engage with students of the Master’s program in Molecular & Cellular Biology at @Sorbonne_Univ_ 💡Empowering future researchers is key to advancing global health #Vaccines #PublicHealth #NextGenScience
0
0
0
🎇Les 2 ans de l'Agence de l'Innovation en Santé Le 4 déc, notre CEO a pris la parole en tant que lauréat #France2030, pour présenter notre approche innovante en matière de vaccination universelle Notre techno➡️ 📸©Benoît GRANIER / Matignon @SGPI_avenir
0
0
0
[Flu Insights] 📽️The Connection Between Flu and Cardiovascular Risks Influenza infection significantly increases the risk for individuals with cardiovascular disease. Watch this video from @VaccinesToday: #HeartHealth #FluVaccine #PublicHealth
0
0
1
💡Reflecting on Osivax at I4ID Last week our team participated in #I4ID2024, proudly presenting two posters showcasing our cutting-edge influenza vaccine research 🙏A big thank you to the organizers @Lyonbiopole @MabDesign_fr 👉 #Innovation #PublicHealth
0
0
0
🚨It’s #NationalInfluenzaVaccinationWeek Dec 2–6! 🗓️ #NIVW is a moment to highlight the importance of staying informed about flu prevention and its impact on global health. Let’s spread the word! #NIVW2024 #FightFlu
@CDCFlu
0
0
0
✨We're delighted to be taking part in this year's @I4IDCongress Several members of our team will be attending, and two posters on our influenza vaccine candidate, OVX836, will be featured 📅November 27-28, 2024 📍Lyon, FR @MabDesign_fr|@Lyonbiopole
#InfectiousDisease #Vaccine
0
0
0
